2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Hall B
Technology and Procedures, Assays, Omics Technologies, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

996 STAG2 loss creates a targetable chromatin-remodeling dependency in acute myeloid leukemia

Viviana Scoca, PhD, Jane J. Xu, PhD2, Alvaro Cuesta-Dominguez, PhD3, Varun Saichandan Sudunagunta, B.A.4, Sebastian Fernando, MS5, Yi Chen, MD, PhD6, Edna Marie Stewart, B.S., M.S.7, Rongjia Deng, MD8, John Pantazi9, Anabella M D Galang10, Stavroula Kousteni, PhD11, Aaron Viny, MD, MS12
1 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
2 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
3 Columbia Herbert Irving Comprehensive Cancer Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
4 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
5 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
6 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
7 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
8 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
9 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
10 Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
11 Columbia Herbert Irving Comprehensive Cancer Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
12 Columbia Herbert Irving Comprehensive Cancer Center, New York, New York, United States, Columbia Stem Cell Initiative, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States

Maintenance of chromatin architecture and accessibility is pivotal for hematopoietic cell identity and prevention of malignant transformation, as well as a key dependency in leukemia. The cohesin complex mediates enhancer-promoter interactions that regulate gene expression. STAG2 is the most frequently mutated cohesin component in myeloid malignancies, occurring in 15-25% of AML with myelodysplasia-related changes (AML-MR) (Lindsley et al., 2015; Papaemmanuil et al., 2016; Jann et al., 2024). STAG2 mutations are associated with significantly worse survival and therapy resistance, even in otherwise favorable-risk AML such as NPM1-mutant disease (Chan et al., 2024; Lachowiez et al., 2025) and STAG2 loss affects chromatin accessibility in myelodysplastic syndrome (MDS) and AML models (Viny et al., 2019; Xu et al., bioRxiv 2025; Sudunagunta et al., 2026). The BAF (SWI/SNF) chromatin remodeling complex acts with pioneer transcription factors, such as PU.1, to modulate accessibility of normal and malignant hematopoietic gene programs via nucleosome sliding. Unlike other cancers, BAF subunits are rarely mutated in AML; instead, BAF is required to maintain chromatin opening at leukemic enhancers (Shi et al., 2013; Chambers et al., 2023; Fiskus et al., 2024). Therapeutic BAF inhibition via FHD-286 (Foghorn Therapeutics) combined with decitabine in relapsed/refractory AML showed antileukemic activity with blast differentiation, but patients did not undergo remission, and differentiation syndrome was the most frequent adverse event (DiNardo et al., 2025).

Given the independent roles of STAG2-cohesin and BAF in licensing accessibility and sustaining leukemia, we hypothesized that STAG2-mutant AML is selectively dependent on BAF-mediated chromatin remodeling. Supporting this possibility, analysis of the BEAT-AML cohort revealed significant upregulation of the BAF-complex components ARID1B (cBAF), BRD7 (PBAF), and SMARCD3 (shared cBAF/PBAF) in STAG2-mutant AML compared with STAG2 wild-type (WT), suggesting a disease-specific dependency on BAF-mediated chromatin remodeling.

To model STAG2-mutant AML, which predominantly harbors loss-of-function mutations, we generated STAG2 knockout (KO) OCI-AML3 (NPM1-mutant) clones by CRISPR-Cas9 using two independent sgRNAs, in parallel with two non-targeting sgRNAs. STAG2 KO cells showed greater sensitivity to FHD-286 than isogenic control cells (IC50 ~12 vs ~24 nM, day 7). For subsequent studies we employed two preclinically established doses (10 and 30 nM).

STAG2 KO cells displayed enhanced apoptosis and stronger cell-cycle suppression following treatment but attenuated myeloid differentiation with blunted CD11b upregulation. To define the mechanistic basis of this dependency, we performed RNA-seq, ATACseq, and CUT&RUN analyses of treated cells compared to untreated control for both STAG2 KO and STAG2 WT cells. GSEA at an early timepoint (day 3) highlighted selective suppression of monocyte and neutrophil fate programs in STAG2-deficient cells, with stronger downregulation of MYC targets and cell cycle progression genes at 30 nM. FHD-286 treatment drove an enhancer-biased loss of chromatin accessibility. ATAC-seq demonstrated that BAF inhibition induced enhancer-centered chromatin collapse in both genotypes, but STAG2-deficient cells exhibited substantially greater enhancer loss (~10,700 vs ~8,900 peaks at 10 nM and ~19,700 vs ~15,000 peaks at 30 nM), consistent with increased dependence on BAF-mediated chromatin remodeling. Lost accessibility was enriched at PU.1, SpiB, IRF8, and RUNX-family motifs, indicating preferential destabilization of lineage-specifying enhancers. PU.1 CUT&RUN further showed that FHD-286 abolished PU.1 occupancy at leukemic enhancers in STAG2-deficient cells and impaired PU.1 recruitment to myeloid differentiation targets, unlike STAG2 WT cells, indicating STAG2-deficient leukemias cannot re-establish PU.1-dependent lineage programs following BAF inhibition.

Together, these studies identify a synthetic chromatin vulnerability created by STAG2 loss. BAF inhibition induces enhancer collapse in all AML cells, but STAG2-deficient leukemias exhibit amplified chromatin disruption, increased apoptosis, and inability to restore PU.1-dependent lineage programs. These findings suggest that STAG2-mutant AML is dependent on BAF-mediated enhancer maintenance and nominate chromatin-remodeling inhibition as a precision therapeutic strategy for cohesin-mutant disease.

Viviana Scoca, PhD: No relevant conflicts of interest to declare.